1
|
Fukunaga K, Tsukagoshi E, Nakamura R, Matsunaga K, Ozeki T, Watanabe H, Hasegawa A, Hama N, Kurata M, Mizukawa Y, Watanabe Y, Yamaguchi Y, Niihara H, Morita E, Asada H, Abe R, Saito Y, Mushiroda T. Association of HLA-A∗11:01, HLA-B∗39:01, and HLA-B∗56:03 with salazosulfapyridine-induced cutaneous adverse drug reactions. J Allergy Clin Immunol Pract 2024:S2213-2198(24)00273-3. [PMID: 38613561 DOI: 10.1016/j.jaip.2024.02.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 02/27/2024] [Accepted: 02/29/2024] [Indexed: 04/15/2024]
Affiliation(s)
- Koya Fukunaga
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Eri Tsukagoshi
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Ryosuke Nakamura
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Kayoko Matsunaga
- Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Hideaki Watanabe
- Department of Dermatology, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - Akito Hasegawa
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Natsumi Hama
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Maiko Kurata
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Yoshiko Mizukawa
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Yuko Watanabe
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yukie Yamaguchi
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiroyuki Niihara
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Eishin Morita
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Hideo Asada
- Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, Japan
| | - Riichiro Abe
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
| |
Collapse
|
2
|
Fukunaga K, Tsukagoshi E, Kurata M, Mizukawa Y, Niihara H, Morita E, Watanabe Y, Yamaguchi Y, Watanabe H, Nakajima S, Nomura T, Kabashima K, Tohyama M, Azukizawa H, Asada H, Hasegawa A, Hama N, Ozeki T, Mashimo Y, Sekine A, Matsunaga K, Tanaka Y, Nakamura R, Abe R, Mushiroda T, Saito Y. Differential Effects of HLA-B∗15:11 and HLA-A∗31:01 on Carbamazepine-Induced Cutaneous Adverse Reactions. J Invest Dermatol 2024; 144:908-911.e7. [PMID: 37914023 DOI: 10.1016/j.jid.2023.09.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 09/08/2023] [Accepted: 09/27/2023] [Indexed: 11/03/2023]
Affiliation(s)
- Koya Fukunaga
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Eri Tsukagoshi
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Maiko Kurata
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Yoshiko Mizukawa
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Hiroyuki Niihara
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Eishin Morita
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Yuko Watanabe
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Yukie Yamaguchi
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hideaki Watanabe
- Department of Dermatology, Showa University Northern Yokohama Hospital, Yokohama, Japan
| | - Saeko Nakajima
- Department of Dermatology, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - Takashi Nomura
- Department of Dermatology, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - Kenji Kabashima
- Department of Dermatology, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan
| | - Mikiko Tohyama
- Department of Dermatology, National Hospital Organization Shikoku Cancer Center, Japan
| | - Hiroaki Azukizawa
- Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, Japan
| | - Hideo Asada
- Department of Dermatology, School of Medicine, Nara Medical University, Kashihara, Japan
| | - Akito Hasegawa
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Natsumi Hama
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yoichi Mashimo
- Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Akihiro Sekine
- Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Kayoko Matsunaga
- Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan
| | - Yoichi Tanaka
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Ryosuke Nakamura
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Riichiro Abe
- Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
| | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| |
Collapse
|
3
|
Ozeki T, Muramatsu K, Yoshimoto N, Ujiie I, Izumi K, Iwata H, Mushiroda T, Ujiie H. Association of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors. J Invest Dermatol 2023; 143:2219-2225.e5. [PMID: 37156394 DOI: 10.1016/j.jid.2023.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 03/24/2023] [Accepted: 04/17/2023] [Indexed: 05/10/2023]
Abstract
Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. Several factors, including an antidiabetic (dipeptidyl peptidase-4 inhibitor [DPP-4i]), have been reported to trigger BP. To identify the genetic variants associated with BP, GWAS and HLA fine-mapping analyses were conducted. The 21 cases of noninflammatory BP induced by DPP-4i (i.e., DPP-4i-induced noninflammatory BP) and 737 controls (first cohort) and the 8 cases and 164 controls (second cohort) were included in the GWAS. Combining GWAS satisfied the genome-wide significant association of HLA-DQA1 (chromosome 6, rs3129763 [T/C]) with the risk of DPP-4i-induced noninflammatory BP (allele T carrier of 72.4% [21 of 29] in cases vs. 15.3% [138 of 901] in controls; dominant model, OR = 14, P = 1.8 × 10-9). HLA fine mapping revealed that HLA-DQA1∗05 with serine at position 75 of HLA-DQα1 (Ser75) had the most significant association with the combined cohort of DPP-4i-induced noninflammatory BP (79.3% [23 of 29] cases vs. 16.1% [145 of 901] controls; dominant model, OR = 21, P = 2.0 × 10-10). HLA-DQα1 Ser75 polymorphism was located inside the functional pocket of HLA-DQ molecules, suggesting the impact of HLA-DQα1 Ser75 on DPP-4i-induced noninflammatory BP.
Collapse
Affiliation(s)
- Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Ken Muramatsu
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Norihiro Yoshimoto
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Inkin Ujiie
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Kentaro Izumi
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroaki Iwata
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Hideyuki Ujiie
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
| |
Collapse
|
4
|
Ishii Y, Aiba N, Ando M, Asakura N, Bierwage A, Cara P, Dzitko H, Edao Y, Gex D, Hasegawa K, Hayashi T, Hiwatari R, Hoshino T, Ikeda Y, Ishida S, Isobe K, Iwai Y, Jokinen A, Kasugai A, Kawamura Y, Kim JH, Kondo K, Kwon S, Lorenzo SC, Masuda K, Matsuyama A, Miyato N, Morishita K, Nakajima M, Nakajima N, Nakamichi M, Nozawa T, Ochiai K, Ohta M, Oyaidzu M, Ozeki T, Sakamoto K, Sakamoto Y, Sato S, Seto H, Shiroto T, Someya Y, Sugimoto M, Tanigawa H, Tokunaga S, Utoh H, Wang W, Watanabe Y, Yagi M. R&D Activities for Fusion DEMO in the QST Rokkasho Fusion Institute. Fusion Science and Technology 2021. [DOI: 10.1080/15361055.2021.1925030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Y. Ishii
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Aiba
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - M. Ando
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Asakura
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - A. Bierwage
- National Institutes for Quantum and Radiological Science and Technology, Naka Fusion Institute, Naka City, Japan
| | - P. Cara
- IFMIF/EVEDA Project Team, Rokkasho-Vill., Japan
| | - H. Dzitko
- Fusion for Energy, Broader Approach, Garching, Germany
| | | | - D. Gex
- Fusion for Energy, Broader Approach, Garching, Germany
| | - K. Hasegawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Hayashi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - R. Hiwatari
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Hoshino
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Ikeda
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Ishida
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Isobe
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Iwai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - A. Jokinen
- IFMIF/EVEDA Project Team, Rokkasho-Vill., Japan
| | - A. Kasugai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Kawamura
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - J. H. Kim
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Kondo
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Kwon
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. C. Lorenzo
- Fusion for Energy, Broader Approach, Barcelona, Spain
| | - K. Masuda
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - A. Matsuyama
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Miyato
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Morishita
- Kyoto University, Institute of Advanced Energy, Uji, Japan
| | - M. Nakajima
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - N. Nakajima
- National Institute for Fusion Science, Department of Helical Plasma Research Rokkasho Research Center, Rokkasho-Vill., Japan
| | - M. Nakamichi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Nozawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - K. Ochiai
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Ohta
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Oyaidzu
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Ozeki
- NAT Corporation, Tohoku Branch Office, Rokkasho-Vill., Japan
| | - K. Sakamoto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Sakamoto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Sato
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - H. Seto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - T. Shiroto
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Someya
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Sugimoto
- NAT Corporation, Tohoku Branch Office, Rokkasho-Vill., Japan
| | - H. Tanigawa
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - S. Tokunaga
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - H. Utoh
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - W. Wang
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - Y. Watanabe
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| | - M. Yagi
- National Institutes for Quantum and Radiological Science and Technology, Rokkasho Fusion Institute, Rokkasho-Vill., Japan
| |
Collapse
|
5
|
Hikino K, Abe Y, Sakashita K, Ozeki T, Mushiroda T. Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children's hospital in Japan: A retrospective observational cohort study. Epilepsy Res 2021; 173:106614. [PMID: 33740697 DOI: 10.1016/j.eplepsyres.2021.106614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 03/05/2021] [Accepted: 03/09/2021] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The aim of this study was to explore the prescription pattern of antiepileptics and the relationship between antiepileptics and adverse drug reactions (ADRs) in a Japanese population. METHODS A retrospective observational cohort study was conducted by reviewing the medical records of patients who visited or were admitted to a single tertiary care center between January 2011 and June 2019, were treated with antiepileptics, and developed allergic ADRs associated with these drugs. RESULTS In total, 14,230 unique patients received antiepileptics during the study period. Diazepam was the most frequently used antiepileptic drug (74.8 %), followed by phenobarbital (14.3 %), valproic acid (11.4 %), fosphenytoin (10.0 %), and carbamazepine (7.3 %). Although a trend of increasing prevalence of newer generation antiepileptics was noted, most patients are still treated with older generation antiepileptics. Thirty-two (0.22 %) unique patients experienced ADRs associated with antiepileptics, and the antiepileptic drug most frequently associated with ADRs was carbamazepine, at a rate of 1.4 %. Three patients developed Stevens-Johnson syndrome/toxic epidermal necrolysis, in two of which carbamazepine was implicated. Most patients experienced ADRs associated with aromatic antiepileptics (84.4 %) or older generation antiepileptics (81.3 %). SIGNIFICANCE This is the first study to assess the relationship between ADRs and antiepileptics at a tertiary care center in Japan. Based on our results, most patients were prescribed older generation antiepileptics, and most ADR events were linked to the administration of drugs in this category; thus, identification of patients at risk of developing ADRs is critical in order to prevent such events.
Collapse
Affiliation(s)
- Keiko Hikino
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan.
| | - Yuichi Abe
- Division of Neurology, Department of Medical Subspecialties, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan
| | - Kazumi Sakashita
- Department of General Pediatrics & Interdisciplinary Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan
| |
Collapse
|
6
|
Tokunaga S, Moreau P, Signoret J, Imbeaux F, Tsitrone E, Loarer T, Salmon T, Hutter T, Giruzzi G, Joffrin E, De Tommasi G, Sartori F, Farthing J, Nakanishi H, Ozeki T, Asakura N, Sakamoto Y, Ohtsu H, Sugie Y, Suzuki S, Fukuda M, Nakano T, Sano R, Ishii Y, Clement-Lorenzo S, Nakajima N. Remote experiment with WEST from ITER Remote Experimentation Centre. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111554] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Nakamura R, Ozeki T, Hirayama N, Sekine A, Yamashita T, Mashimo Y, Mizukawa Y, Shiohara T, Watanabe H, Sueki H, Ogawa K, Asada H, Kaniwa N, Tsukagoshi E, Matsunaga K, Niihara H, Yamaguchi Y, Aihara M, Mushiroda T, Saito Y, Morita E. Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. J Invest Dermatol 2020; 140:1659-1662.e6. [PMID: 31981579 DOI: 10.1016/j.jid.2019.12.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 12/03/2019] [Accepted: 12/28/2019] [Indexed: 02/02/2023]
Affiliation(s)
- Ryosuke Nakamura
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Noriaki Hirayama
- Institute of Advanced Biosciences, Tokai University, Kanagawa, Japan
| | - Akihiro Sekine
- Center for Preventive Medical Science, Chiba University, Chiba, Japan
| | - Taiki Yamashita
- Center for Preventive Medical Science, Chiba University, Chiba, Japan
| | - Yoichi Mashimo
- Center for Preventive Medical Science, Chiba University, Chiba, Japan
| | - Yoshiko Mizukawa
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Tetsuo Shiohara
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Hideaki Watanabe
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Hirohiko Sueki
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Kohei Ogawa
- Department of Dermatology, Nara Medical University, Nara, Japan
| | - Hideo Asada
- Department of Dermatology, Nara Medical University, Nara, Japan
| | - Nahoko Kaniwa
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Eri Tsukagoshi
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan
| | - Kayoko Matsunaga
- Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Aichi, Japan
| | - Hiroyuki Niihara
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
| | - Yukie Yamaguchi
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Michiko Aihara
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
| | - Eishin Morita
- Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan
| |
Collapse
|
8
|
Hikino K, Ozeki T, Koido M, Terao C, Kamatani Y, Mizukawa Y, Shiohara T, Tohyama M, Azukizawa H, Aihara M, Nihara H, Morita E, Murakami Y, Kubo M, Mushiroda T. HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project. Clin Pharmacol Ther 2019; 107:1170-1178. [PMID: 31646624 DOI: 10.1002/cpt.1706] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 10/13/2019] [Indexed: 12/19/2022]
Abstract
CYP2C9*3 and HLA-B alleles are reportedly associated with phenytoin-induced eruption in some East Asian populations; however, this finding is not readily applicable to the Japanese population. Thus, we aimed to investigate the risk alleles using samples and data from BioBank Japan. A total of 747 patients (24 cases and 723 tolerant controls) were selected for analysis. Case-control association studies were conducted, using CYP2C9*3, CYP2C9*27, CYP2C19*2, CYP2C19*3, and HLA-B allele genotype data. CYP2C9*3 carrier status was significantly associated with phenytoin-induced eruption (P = 0.0022, odds ratio 7.05, 95% confidence interval, 2.44-20.4). HLA-B*51:01 showed the most prominent association (P = 0.010, odds ratio 3.19, 95% confidence interval, 1.37-7.48). Including both of these features improved predictive performance, measured as area under the receiver operating characteristic curve, by 10%. CYP2C9*3 and HLA-B*51:01 allele carrier statuses are significantly associated with phenytoin-induced eruption; thus, checking this carrier status before prescription would decrease the incidence of phenytoin-induced eruption in clinical practice.
Collapse
Affiliation(s)
- Keiko Hikino
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| | - Masaru Koido
- Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| | - Chikashi Terao
- Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| | - Yoichiro Kamatani
- Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan.,Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Yoshiko Mizukawa
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Tetsuo Shiohara
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Mikiko Tohyama
- Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan
| | - Hiroaki Azukizawa
- Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Michiko Aihara
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiroyuki Nihara
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Eishin Morita
- Department of Dermatology, Faculty of Medicine, Shimane University, Shimane, Japan
| | - Yoshinori Murakami
- Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Michiaki Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Kanagawa, Japan
| |
Collapse
|
9
|
Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, Takeuchi K, Otsuka K, Okazaki M, Watanabe M, Kanemoto K, Oshima T, Watanabe A, Minami S, Saito K, Tanii H, Shimo Y, Hara M, Saitoh S, Kinoshita T, Kato M, Yamada N, Akamatsu N, Fukuchi T, Ishida S, Yasumoto S, Takahashi A, Ozeki T, Furuta T, Saito Y, Izumida N, Kano Y, Shiohara T, Kubo M. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurol 2019; 75:842-849. [PMID: 29610831 DOI: 10.1001/jamaneurol.2018.0278] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Importance Carbamazepine, a commonly used antiepileptic drug, is one of the most common causes of cutaneous adverse drug reactions (cADRs) worldwide. The allele HLA-A*31:01 is reportedly associated with carbamazepine-induced cADRs in Japanese and European populations; however, the clinical utility of HLA-A*31:01 has not been evaluated. Objective To assess the use of HLA-A*31:01 genetic screening to identify Japanese individuals at risk of carbamazepine-induced cADRs. Design, Setting, and Participants This cohort study was conducted across 36 hospitals in Japan from January 2012 to November 2014 among 1202 patients who had been deemed suitable to start treatment with carbamazepine. Preemptive HLA-A*31:01 genetic screening was performed for 1187 participants. Patients who did not start treatment with carbamazepine or alternative drugs were excluded. Participants were interviewed once weekly for 8 weeks to monitor the development of cADRs. Data analysis was performed from June 8, 2015, to December 27, 2016. Exposures Neuropsychiatrists were asked to prescribe carbamazepine for patients who tested negative for HLA-A*31:01 and alternative drugs for those who tested positive for HLA-A*31:01. Main Outcomes and Measures Incidence of carbamazepine-induced cADRs. Results Of the 1130 included patients who were prescribed carbamazepine or alternative drugs, the mean (range) age was 37.4 (0-95) years, 614 (54.3%) were men, and 198 (17.5%) were positive for HLA-A*31:01. Expert dermatologists identified 23 patients (2.0%) who had carbamazepine-induced cADRs, of which 4 patients required hospitalization. Drug-induced hypersensitivity syndrome was observed for 3 patients, maculopapular eruption for 9 patients, erythema multiforme for 5 patients, and an undetermined type of cADR for 6 patients. No patient developed Stevens-Johnson syndrome or toxic epidermal necrolysis. Compared with historical controls, the incidence of carbamazepine-induced cADRs was significantly decreased (for BioBank Japan data: incidence, 3.4%; odds ratio, 0.60; 95% CI, 0.36-1.00; P = .048; for the Japan Medical Data Centre claims database: incidence, 5.1%; odds ratio, 0.39; 95% CI, 0.26-0.59; P < .001). Conclusions and Relevance Preemptive HLA-A*31:01 genetic screening significantly decreased the incidence of carbamazepine-induced cADRs among Japanese patients, which suggests that it may be warranted in routine clinical practice.
Collapse
Affiliation(s)
| | - Yukitoshi Takahashi
- Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
| | | | - Yoshiaki Yamamoto
- Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan
| | | | - Tohru Hoshida
- National Hospital Organization Nara Medical Center, Nara, Japan
| | - Katsuya Takeuchi
- Department of Neuropsychiatry, Iwate Medical University, Iwate, Japan.,Kitariasu Hospital, Iwate, Japan
| | - Kotaro Otsuka
- Department of Neuropsychiatry, Iwate Medical University, Iwate, Japan
| | - Mitsutoshi Okazaki
- Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - Masako Watanabe
- Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - Kosuke Kanemoto
- Neuropsychiatric Department, Aichi Medical University, Aichi, Japan
| | - Tomohiro Oshima
- Neuropsychiatric Department, Aichi Medical University, Aichi, Japan
| | - Atsushi Watanabe
- Division of Personalized Genetic Medicine, Nippon Medical School, Tokyo, Japan
| | - Shiro Minami
- Institute for Advanced Medical Sciences, Nippon Medical School, Kawasaki, Japan
| | - Kayoko Saito
- Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan
| | - Hisashi Tanii
- Department of Psychiatry, Mie University Graduate School of Medicine, Mie, Japan
| | - Yasushi Shimo
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | | | - Shinji Saitoh
- Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | | | - Masaki Kato
- Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
| | - Naoto Yamada
- Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan
| | - Naoki Akamatsu
- Department of Neurology, University of Occupational and Environmental Health, Kitakyusyu, Japan
| | | | - Shigenobu Ishida
- Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan
| | - Shingo Yasumoto
- Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan
| | | | - Takeshi Ozeki
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Takahisa Furuta
- Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Nobuyuki Izumida
- Department of Empirical Social Security Research, National Institute of Population and Social Security Research, Tokyo, Japan
| | - Yoko Kano
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Tetsuo Shiohara
- Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Michiaki Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | | |
Collapse
|
10
|
Tsuda K, Kanzaki Y, Maeda D, Akamatsu K, Nakayama S, Horai R, Sakane K, Ozeki T, Fujita S, Fujisaka T, Sohmiya K, Hoshiga M. P6257Low systolic blood pressure on admission as a predictor of outcome in octogenarian patients with heart failure and preserved ejection fraction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is an epidemic in healthcare worldwide including Asia. It appears that HF will become more serious with aging of the population. The patients with heart failure and preserved ejection fraction (HFpEF) were older, more often female, and frequently have comorbidities including hypertension. However, lower systolic blood pressure (SBP) on admission is associated with poor outcomes in patients with HF. It remains unclear whether this association is similar in very elderly patients with HFpEF.
Purpose
To investigate clinical features and prognosis in octogenarian HFpEF subjects.
Methods
We analyzed 87 consecutive subjects aged 80 years or older who were hospitalized for acute decompensated HF with left ventricular ejection fraction (LVEF) ≥50% between 2015 and 2017. Clinical characteristics and a composite event of cardiac death and HF hospitalization were compared in two groups according to SBP cut-off of 140 mmHg on admission.
Results
The prevalence of lower SBP subjects (mean BP = 118 mmHg) and higher SBP (mean BP = 166 mmHg) subjects were 41.4% and 58.6%, respectively. Lower SBP subjects were more comorbid with atrial fibrillation (72.2 vs. 45.1%, p=0.01). In the lower SBP group, diuretics, mineralocorticoid receptor antagonists (MRA), beta-blockers and ACE inhibitors/ARBs were more commonly used than higher SBP group (Table). During the observational period (median = 1.0 year), lower SBP on admission was associated with a 2.65-fold [95% confidence interval (CI): 1.29–5.55, p=0.009] greater likelihood of experiencing the composite events of cardiac death and rehospitalization for HF (Figure). This observation was still consistent even after adjusting clinical demographics and comorbidity [hazard ratio = 2.95, 95% CI: 1.30–6.87, p=0.01].
Table 1 Lower SBP group (n=36) Higher SBP group (n=51) P-value Atrial fibrillation (%) 72.2 0.01 0.01 Loop diuretic (%) 97.1 83.7 0.08 MRA (%) 47.1 24.5 0.04 Beta-blocker (%) 52.9 44.9 0.51 ACE inhibitor/ARB (%) 59.2 29.4 0.01
Figure 1
Conclusions
In octogenarian patients with acute decompensated HF and preserved LVEF, SBP on admission less than 140 mmHg is significantly associated with poor outcomes. Future studies need to prospectively evaluate optimal SBP treatment goals in very elderly patients with HFpEF.
Collapse
Affiliation(s)
- K Tsuda
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - Y Kanzaki
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - D Maeda
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - K Akamatsu
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - S Nakayama
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - R Horai
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - K Sakane
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - T Ozeki
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - S Fujita
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - T Fujisaka
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - K Sohmiya
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| | - M Hoshiga
- Osaka Medical College, Department of Cardiology, Takatsuki, Japan
| |
Collapse
|
11
|
Farthing J, Ozeki T, Clement Lorenzo S, Nakajima N, Sartori F, De Tommasi G, Manduchi G, Barbato P, Rigoni A, Vitale V, Giruzzi G, Mattei M, Mele A, Imbeaux F, Artaud JF, Robin F, Noe J, Joffrin E, Hynes A, Hemming O, Wheatley M, O’hira S, Ide S, Ishii Y, Matsukawa M, Kubo H, Totsuka T, Urano H, Naito O, Hayashi N, Miyata Y, Namekawa M, Wakasa A, Oshima T, Nakanishi H, Yamanaka K. Status of the ITER remote experimentation centre. Fusion Engineering and Design 2018. [DOI: 10.1016/j.fusengdes.2018.02.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Sato N, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H. HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol 2017; 138:1201-1204. [PMID: 29203362 DOI: 10.1016/j.jid.2017.11.023] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Revised: 10/29/2017] [Accepted: 11/14/2017] [Indexed: 12/29/2022]
Affiliation(s)
- Hideyuki Ujiie
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
| | - Ken Muramatsu
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Hideaki Miyoshi
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroaki Iwata
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Akinobu Nakamura
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroshi Nomoto
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Kyu Yong Cho
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Norihiro Sato
- Hokkaido University Hospital Clinical Research and Medical Innovation Center, Sapporo, Japan
| | - Machiko Nishimura
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Takamasa Ito
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Kentaro Izumi
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Wataru Nishie
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - Hiroshi Shimizu
- Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| |
Collapse
|
13
|
Watanabe H, Watanabe Y, Tashiro Y, Mushiroda T, Ozeki T, Hashizume H, Sueki H, Yamamoto T, Utsunomiya-Tate N, Gouda H, Kusakabe Y. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. J Dermatol Sci 2017; 88:320-329. [PMID: 28870516 DOI: 10.1016/j.jdermsci.2017.08.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Revised: 07/04/2017] [Accepted: 08/08/2017] [Indexed: 12/20/2022]
Abstract
BACKGROUND Dapsone (4,4'-diaminodiphenylsulfone) has been widely used for the treatment of infections such as leprosy. Dapsone hypersensitivity syndrome (DHS) is a major side effect, developing in 0.5-3.6% of patients treated with dapsone, and its mortality rate is ∼10%. Recently, human leukocyte antigen (HLA)-B*13:01 was identified as a marker of susceptibility to DHS. OBJECTIVES To investigate why HLA-B*13:01 is responsible for DHS from a structural point of view. METHODS First, we used homology modeling to derive the three-dimensional structures of HLA-B*13:01 (associated with DHS) and HLA-B*13:02 (not so associated despite strong sequence identity [99%] with HLA-B*13:01). Next, we used molecular docking, molecular dynamic simulations, and the molecular mechanics Poisson-Boltzman surface area method, to investigate the interactions of dapsone with HLA-B*13:01 and 13:02. RESULTS We found a crucial structural difference between HLA-B*13:01 and 13:02 in the F-pocket of the antigen-binding site. As Trp95 in the α-domain of HLA-B*13:02 is replaced with the less bulky Ile95 in HLA-B*13:01, we found an additional well-defined sub-pocket within the antigen-binding site of HLA-B*13:01. All three representative docking poses of dapsone against the antigen-binding site of HLA-B*13:01 used this unique sub-pocket, indicating its suitability for binding dapsone. However, HLA-B*13:02 does not seem to possess a binding pocket suitable for binding dapsone. Finally, a binding free energy calculation combined with a molecular dynamics simulation and the molecular mechanics Poisson-Boltzman surface area method indicated that the binding affinity of dapsone for HLA-B*13:01 would be much greater than that for HLA-B*13:02. CONCLUSIONS Our computational results suggest that dapsone would fit within the structure of the antigen-recognition site of HLA-B*13:01. This may change the self-peptides that bind to HLA-B*13:01, explaining why HLA-B*13:01 is a marker of DHS susceptibility.
Collapse
Affiliation(s)
- Hideaki Watanabe
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
| | - Yurie Watanabe
- Department of Analytical and Physical Chemistry, Showa University School of Pharmacy, Tokyo, Japan
| | - Yasuya Tashiro
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | | | - Takeshi Ozeki
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Hideo Hashizume
- Department of Dermatology, Shimada Municipal Hospital, Shizuoka, Japan
| | - Hirohiko Sueki
- Department of Dermatology, Showa University School of Medicine, Tokyo, Japan
| | - Toshinori Yamamoto
- Showa University Medical Foundation, Showa University School of Pharmacy, Tokyo, Japan
| | - Naoko Utsunomiya-Tate
- Laboratory of Chemistry, Faculty of Pharma Sciences, Teikyo University, Tokyo, Japan
| | - Hiroaki Gouda
- Department of Analytical and Physical Chemistry, Showa University School of Pharmacy, Tokyo, Japan.
| | - Yoshio Kusakabe
- Department of Analytical and Physical Chemistry, Showa University School of Pharmacy, Tokyo, Japan; Laboratory of Chemistry, Faculty of Pharma Sciences, Teikyo University, Tokyo, Japan
| |
Collapse
|
14
|
Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I. Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer Sci 2017; 108:1843-1849. [PMID: 28667792 PMCID: PMC5581516 DOI: 10.1111/cas.13309] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 06/20/2017] [Accepted: 06/27/2017] [Indexed: 12/23/2022] Open
Abstract
Spliced variant isoforms of CD44 (CD44v) are a marker of cancer stem cells in solid tumors. They stabilize the xCT subunit of the transporter system xc(–) and thereby promote synthesis of the antioxidant glutathione. Salazosulfapyridine (SASP) is an inhibitor of xCT and suppresses the proliferation of CD44v‐positive cancer cells. Chemotherapy‐naïve patients with advanced non‐squamous non‐small‐cell lung cancer were enrolled in a dose‐escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed. The primary end‐point was the percentage of patients who experience dose‐limiting toxicity. Fifteen patients were enrolled in the study. Dose‐limiting toxicity was observed in one of six patients at a SASP dose of 1.5 g/day (elevation of aspartate and alanine aminotransferase levels, each of grade 3), two of five patients at 3 g/day (hypotension or pneumonitis, each of grade 3), and two of three patients at 4.5 g/day (anorexia of grade 3). The maximum tolerated dose was thus 3 g/day, and the recommended dose was 1.5 g/day. The overall response rate was 26.7% and median progression‐free survival was 11.7 months, much longer than that for cisplatin–pemetrexed alone in previous studies. Exposure to SASP varied markedly among individuals according to ABCG2 and NAT2 genotypes. The serum concentration of free CD44v protein was increased after the first cycle of treatment, possibly reflecting death of cancer stem cells. Salazosulfapyridine was thus given safely in combination with cisplatin–pemetrexed, with the addition of SASP tending to prolong progression‐free survival. This trial is registered in the UMIN Clinical Trials Registry as UMIN000017854.
Collapse
Affiliation(s)
- Kohei Otsubo
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Kaname Nosaki
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Chiyo K Imamura
- Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan
| | - Hiroaki Ogata
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Akitaka Fujita
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Shinya Sakata
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Fumihiko Hirai
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Gouji Toyokawa
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | - Eiji Iwama
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Taishi Harada
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takashi Seto
- Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan
| | | | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Japan
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama City, Japan
| | - Mieko Inada
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
| | - Junji Kishimoto
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
| | - Kenji Tsuchihashi
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Kentaro Suina
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Osamu Nagano
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Hideyuki Saya
- Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
| | - Yoichi Nakanishi
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
| | - Isamu Okamoto
- Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
15
|
Saito T, Ikeda M, Hashimoto R, Iwata N, Yamamori H, Yasuda Y, Fujimoto M, Kondo K, Shimasaki A, Kawase K, Miyata M, Mushiroda T, Ozeki T, Kubo M, Fujita K, Kida N, Nakai M, Otsuru T, Fukuji Y, Murakami M, Mizuno K, Shiratsuchi T, Numata S, Ohmori T, Ueno SI, Yada Y, Tanaka S, Kishi Y, Takaki M, Mamoto A, Taniguchi N, Sawa Y, Watanabe H, Noda T, Amano Y, Kimura T, Fukao T, Suwa T, Murai T, Kubota M, Ueda K, Tabuse H, Kanahara N, Kawai N, Nemoto K, Makinodan M, Nishihata Y, Hashimoto N, Kusumi I, Fujii Y, Miyata R, Hirakawa K, Ozaki N. Transethnic Replication Study to Assess the Association Between Clozapine-Induced Agranulocytosis/Granulocytopenia and Genes at 12p12.2 in a Japanese Population. Biol Psychiatry 2017; 82:e9-e10. [PMID: 28161127 DOI: 10.1016/j.biopsych.2016.12.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 10/31/2016] [Accepted: 12/09/2016] [Indexed: 12/01/2022]
Affiliation(s)
- Takeo Saito
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Masashi Ikeda
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Ryota Hashimoto
- Department of Psychiatry, Osaka University Graduate School of Medicine; Molecular Research Center for Children׳s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan
| | - Nakao Iwata
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi.
| | | | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate School of Medicine
| | - Yuka Yasuda
- Department of Psychiatry, Osaka University Graduate School of Medicine
| | - Michiko Fujimoto
- Department of Psychiatry, Osaka University Graduate School of Medicine
| | - Kenji Kondo
- Department of Psychiatry, Fujita Health University School of Medicine
| | - Ayu Shimasaki
- Department of Psychiatry, Fujita Health University School of Medicine
| | - Kohei Kawase
- Department of Psychiatry, Fujita Health University School of Medicine
| | - Masami Miyata
- Center for Research Promotion and Support, Fujita Health University
| | - Taisei Mushiroda
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences
| | - Takeshi Ozeki
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences
| | | | | | - Naoya Kida
- National Hospital Organization Ryukyu Hospital
| | | | - Taku Otsuru
- National Hospital Organization Ryukyu Hospital
| | | | | | | | | | - Shusuke Numata
- Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School
| | - Tetsuro Ohmori
- Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School
| | - Shu-Ichi Ueno
- Department of Neuropsychiatry, Ehime University Graduate School of Medicine
| | | | | | | | - Manabu Takaki
- Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
| | | | | | | | | | | | | | - Takemi Kimura
- Division of Clinical Research, National Hospital Organization Kikuchi Hospital
| | - Taku Fukao
- Department of Psychiatry, Gifu University Graduate School of Medicine
| | - Taro Suwa
- Department of Psychiatry, Graduate School of Medicine, Kyoto University
| | - Toshiya Murai
- Department of Psychiatry, Graduate School of Medicine, Kyoto University
| | | | | | | | | | | | - Kiyotaka Nemoto
- Department of Psychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba
| | - Manabu Makinodan
- Department of Psychiatry, Faculty of Medicine, Nara Medical University
| | - Yosuke Nishihata
- Department of Psychiatry, Faculty of Medicine, Nara Medical University
| | - Naoki Hashimoto
- Department of Psychiatry, Hokkaido University Graduate School of Medicine
| | - Ichiro Kusumi
- Department of Psychiatry, Hokkaido University Graduate School of Medicine
| | | | | | | | - Norio Ozaki
- Department of Psychiatry, Nagoya University Graduate School of Medicine
| |
Collapse
|
16
|
Fukuda T, Oikawa T, Takeji S, Isayama A, Kawano Y, Neyatani Y, Nagashima A, Nishitani T, Konoshima S, Tamai H, Fujita T, Sakamoto Y, Kamada Y, Ide S, Koide Y, Takenaga H, Kurihara K, Sakata S, Ozeki T, Kawamata Y, Miura YM. Advanced Real-Time Feedback Control in JT-60U High Performance Discharges for Application to Fusion Reactor Plasmas. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a233] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Fukuda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Takeji
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kawano
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - A. Nagashima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Nishitani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Konoshima
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Tamai
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kamada
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Ide
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Koide
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - K. Kurihara
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - S. Sakata
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. Kawamata
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| | - Y. M. Miura
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment Naka-machi, Naka-gun, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
17
|
Kamada Y, Fujita T, Ishida S, Kikuchi M, Ide S, Takizuka T, Shirai H, Koide Y, Fukuda T, Hosogane N, Tsuchiya K, Hatae T, Takenaga H, Sato M, Nakamura H, Naito O, Asakura N, Kubo H, Higashijima S, Miura Y, Yoshino R, Shimizu K, Ozeki T, Hirayama T, Mori M, Sakamoto Y, Kawano Y, Isayama A, Ushigusa K, Ikeda Y, Kimura H, Fujii T, Imai T, Nagami M, Takeji S, Oikawa T, Suzuki T, Nakano T, Oyama N, Sakurai S, Konoshima S, Sugie T, Tobita K, Kondoh T, Tamai H, Neyatani Y, Sakasai A, Kusama Y, Itami K, Shimada M, Ninomiya H, Urano H. Fusion Plasma Performance and Confinement Studies on JT-60 and JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a227] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Kamada
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Ishida
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Kikuchi
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Ide
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Takizuka
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Shirai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Koide
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fukuda
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Hosogane
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Tsuchiya
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Hatae
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Takenaga
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Sato
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Nakamura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - O. Naito
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Asakura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Kubo
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Higashijima
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Miura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - R. Yoshino
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Shimizu
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Hirayama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Mori
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Sakamoto
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Kawano
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Ushigusa
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Ikeda
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Fujii
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Imai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Nagami
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Takeji
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Suzuki
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Nakano
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - N. Oyama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Sakurai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - S. Konoshima
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Sugie
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Tobita
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - T. Kondoh
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Tamai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - A. Sakasai
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - K. Itami
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - M. Shimada
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | - H. Ninomiya
- Japan Atomic Energy Research Institute Naka Fusion Research Establishment, Naka-machi, Naka-gun, Ibaraki-ken, Japan
| | | |
Collapse
|
18
|
Tobita K, Kusama Y, Shinohara K, Nishitani T, Kimura H, Kramer GJ, Nemoto M, Kondoh T, Oikawa T, Morioka A, Hamamatsu K, Wang S, Takeji S, Takechi M, Ishikawa M, Tani K, Saigusa M, Ozeki T. Energetic Particle Experiments in JT-60U and Their Implications for a Fusion Reactor. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a231] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Tobita
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - Y. Kusama
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Shinohara
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Nishitani
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - H. Kimura
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - G. J. Kramer
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Nemoto
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Kondoh
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - A. Morioka
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Hamamatsu
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Wang
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - S. Takeji
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Takechi
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Ishikawa
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - K. Tani
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - M. Saigusa
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute, Naka-machi, Naka-gun, Ibaraki 311-0193, Japan
| |
Collapse
|
19
|
Takeji S, Isayama A, Ozeki T, Tokuda S, Ishii Y, Oikawa T, Ishida S, Kamada Y, Neyatani Y, Yoshino R, Takizuka T, Hayashi N, Fujita T, Kurita G, Matsumoto T, Tuda T. Magnetohydrodynamic Stability of Improved Confinement Plasmas in JT-60U. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a229] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. Takeji
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - A. Isayama
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Ozeki
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - S. Tokuda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - Y. Ishii
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Oikawa
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - S. Ishida
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - Y. Kamada
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - Y. Neyatani
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - R. Yoshino
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Takizuka
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - N. Hayashi
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Fujita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - G. Kurita
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Matsumoto
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | - T. Tuda
- Japan Atomic Energy Research Institute, Naka Fusion Research Establishment 801-1 Mukoyama, Naka-machi, Ibaraki 311-0193, Japan
| | | |
Collapse
|
20
|
Donné AJH, Fasoli A, Ferron J, Gonçalves B, Jardin S, Miura Y, Noterdaeme JM, Ozeki T. Summary of the International Energy Agency Workshop on Burning Plasma Physics and Simulation. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1088] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. J. H. Donné
- FOM-Institute for Plasma Physics Rijnhuizen Association Euratom-FOM Partner in the Trilateral Euregio Cluster P.O. Box 1207, 3430 BE Nieuwegein, The Netherlands
| | - A. Fasoli
- CRPP-EPFL, Association Euratom-Swiss Confederation Lausanne, Switzerland
| | - J. Ferron
- General Atomics, San Diego, California
| | | | - S. Jardin
- Princeton Plasma Physics Laboratory Princeton, New Jersey
| | - Y. Miura
- Japan Atomic Energy Research Institute Naka, Japan
| | - J.-M. Noterdaeme
- Max Planck Institute for Plasmaphysics Euratom Association, Garching, Germany and University Gent, EESA Department, Gent, Belgium
| | - T. Ozeki
- Japan Atomic Energy Research Institute Naka, Japan
| |
Collapse
|
21
|
Ozeki T, Aiba N, Hayashi N, Takizuka T, Sugihara M, Oyama N. Integrated Simulation Code for Burning Plasma Analysis. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1221] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Ozeki
- Japan Atomic Energy Agency 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - N. Aiba
- Japan Atomic Energy Agency 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - N. Hayashi
- Japan Atomic Energy Agency 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - T. Takizuka
- Japan Atomic Energy Agency 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - M. Sugihara
- ITER International Team, Naka Joint Work Site, Naka, Ibaraki 311-0193, Japan
| | - N. Oyama
- Japan Atomic Energy Agency 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| |
Collapse
|
22
|
Takenaga H, Kubo H, Kamada Y, Miura Y, Kishimoto Y, Ozeki T. Study of Impurity Injection Scenario in Burning Plasmas. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1273] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. Takenaga
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - H. Kubo
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - Y. Kamada
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - Y. Miura
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - Y. Kishimoto
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| | - T. Ozeki
- Japan Atomic Energy Agency, 801-1 Mukouyama, Naka, Ibaraki 311-0193, Japan
| |
Collapse
|
23
|
Saito T, Ikeda M, Mushiroda T, Ozeki T, Kondo K, Shimasaki A, Kawase K, Hashimoto S, Yamamori H, Yasuda Y, Fujimoto M, Ohi K, Takeda M, Kamatani Y, Numata S, Ohmori T, Ueno SI, Makinodan M, Nishihata Y, Kubota M, Kimura T, Kanahara N, Hashimoto N, Fujita K, Nemoto K, Fukao T, Suwa T, Noda T, Yada Y, Takaki M, Kida N, Otsuru T, Murakami M, Takahashi A, Kubo M, Hashimoto R, Iwata N. Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese Population. Biol Psychiatry 2016; 80:636-42. [PMID: 26876947 DOI: 10.1016/j.biopsych.2015.12.006] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 10/31/2015] [Accepted: 12/03/2015] [Indexed: 11/17/2022]
Abstract
BACKGROUND Clozapine-induced agranulocytosis (CIA)/clozapine-induced granulocytopenia (CIG) (CIAG) is a life-threatening event for schizophrenic subjects treated with clozapine. METHODS To examine the genetic factor for CIAG, a genome-wide pharmacogenomic analysis was conducted using 50 subjects with CIAG and 2905 control subjects. RESULTS We identified a significant association in the human leukocyte antigen (HLA) region (rs1800625, p = 3.46 × 10(-9), odds ratio [OR] = 3.8); therefore, subsequent HLA typing was performed. We detected a significant association of HLA-B*59:01 with CIAG (p = 3.81 × 10(-8), OR = 10.7) and confirmed this association by comparing with an independent clozapine-tolerant control group (n = 380, p = 2.97 × 10(-5), OR = 6.3). As we observed that the OR of CIA (OR: 9.3~15.8) was approximately double that in CIG (OR: 4.4~7.4), we hypothesized that the CIG subjects were a mixed population of those who potentially would develop CIA and those who would not develop CIA (non-CIA). This hypothesis allowed the proportion of the CIG who were non-CIA to be calculated, enabling us to estimate the positive predictive value of the nonrisk allele on non-CIA in CIG subjects. Assuming this model, we estimated that 1) ~50% of CIG subjects would be non-CIA; and 2) ~60% of the CIG subjects without the risk allele would be non-CIA and therefore not expected to develop CIA. CONCLUSIONS Our results suggest that HLA-B*59:01 is a risk factor for CIAG in the Japanese population. Furthermore, if our model is true, the results suggest that rechallenging certain CIG subjects with clozapine may not be always contraindicated.
Collapse
Affiliation(s)
- Takeo Saito
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Masashi Ikeda
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Taisei Mushiroda
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama
| | - Takeshi Ozeki
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama
| | - Kenji Kondo
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Ayu Shimasaki
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Kohei Kawase
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Shuji Hashimoto
- Department of Hygiene, Fujita Health University School of Medicine, Toyoake, Aichi
| | - Hidenaga Yamamori
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka
| | - Yuka Yasuda
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka
| | - Michiko Fujimoto
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka
| | - Kazutaka Ohi
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka
| | - Masatoshi Takeda
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka; Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka
| | - Yoichiro Kamatani
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama
| | - Shusuke Numata
- Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima
| | - Tetsuro Ohmori
- Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima
| | - Shu-Ichi Ueno
- Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Shitsukawa
| | - Manabu Makinodan
- Department of Psychiatry, Faculty of Medicine, Nara Medical University, Kashihara, Nara
| | - Yosuke Nishihata
- Department of Psychiatry, Faculty of Medicine, Nara Medical University, Kashihara, Nara
| | - Masaharu Kubota
- Kusakabe Memorial Hospital, Yamanasi, Yamanasi; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Takemi Kimura
- Division of Clinical Research, National Hospital Organization Kikuchi Hospital, Koshi, Kumamoto
| | | | - Naoki Hashimoto
- Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido
| | - Kiyoshi Fujita
- Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi
| | - Kiyotaka Nemoto
- Department of Psychiatry, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki
| | - Taku Fukao
- Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu
| | - Taro Suwa
- Department of Psychiatry, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto
| | - Tetsuro Noda
- Osaka Psychiatric Medical Center, Hirakata, Osaka
| | - Yuji Yada
- Okayama Psychiatric Medical Center, Kita-ku, Okayama
| | - Manabu Takaki
- Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama
| | - Naoya Kida
- National Hospital Organization Ryukyu Hospital, Kunigami-gun, Okinawa
| | - Taku Otsuru
- National Hospital Organization Ryukyu Hospital, Kunigami-gun, Okinawa
| | - Masaru Murakami
- National Hospital Organization Ryukyu Hospital, Kunigami-gun, Okinawa
| | - Atsushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama; Laboratory for Omics Informatics, Omics Research Center, National Cerebral and Cardiovascular Center, Osaka
| | - Michiaki Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Ryota Hashimoto
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka; Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka.
| | - Nakao Iwata
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi
| |
Collapse
|
24
|
Affiliation(s)
- Hiroko Miyadera
- Department of Human Genetics, Graduate School of Medicine, The University of Tokyo
- Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine
| | - Takeshi Ozeki
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences
| | - Taisei Mushiroda
- Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences
| | | |
Collapse
|
25
|
De Tommasi G, Manduchi G, Muir D, Ide S, Naito O, Urano H, Clement-Lorenzo S, Nakajima N, Ozeki T, Sartori F. Current status of the European contribution to the Remote Data Access System of the ITER Remote Experimentation Centre. Fusion Engineering and Design 2015. [DOI: 10.1016/j.fusengdes.2015.06.094] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Ueta M, Sawai H, Sotozono C, Hitomi Y, Kaniwa N, Kim MK, Seo KY, Yoon KC, Joo CK, Kannabiran C, Wakamatsu TH, Sangwan V, Rathi V, Basu S, Ozeki T, Mushiroda T, Sugiyama E, Maekawa K, Nakamura R, Aihara M, Matsunaga K, Sekine A, Gomes JÁP, Hamuro J, Saito Y, Kubo M, Kinoshita S, Tokunaga K. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol 2015; 135:1538-45.e17. [PMID: 25672763 DOI: 10.1016/j.jaci.2014.12.1916] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2014] [Revised: 11/27/2014] [Accepted: 12/15/2014] [Indexed: 12/28/2022]
Abstract
BACKGROUND Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes, including the ocular surface, oral cavity, and genitals. These reactions are very rare but are often associated with inciting drugs, infectious agents, or both. OBJECTIVE We sought to identify susceptibility loci for cold medicine-related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement (SMI). METHODS A genome-wide association study was performed in 808 Japanese subjects (117 patients with CM-SJS/TEN with SMI and 691 healthy control subjects), and subsequent replication studies were performed in 204 other Japanese subjects (16 cases and 188 control subjects), 117 Korean subjects (27 cases and 90 control subjects), 76 Indian subjects (20 cases and 56 control subjects), and 174 Brazilian subjects (39 cases and 135 control subjects). RESULTS In addition to the most significant susceptibility region, HLA-A, we identified IKZF1, which encodes Ikaros, as a novel susceptibility gene (meta-analysis, rs4917014 [G vs. T]; odds ratio, 0.5; P = 8.5 × 10(-11)). Furthermore, quantitative ratios of the IKZF1 alternative splicing isoforms Ik1 and Ik2 were significantly associated with rs4917014 genotypes. CONCLUSION We identified IKZF1 as a susceptibility gene for CM-SJS/TEN with SMI not only in Japanese subjects but also in Korean and Indian subjects and showed that the Ik2/Ik1 ratio might be influenced by IKZF1 single nucleotide polymorphisms, which were significantly associated with susceptibility to CM-SJS/TEN with SMI.
Collapse
Affiliation(s)
- Mayumi Ueta
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan; Research Center for Inflammation and Regenerative Medicine, Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan; Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
| | - Hiromi Sawai
- Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Chie Sotozono
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yuki Hitomi
- Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Nahoko Kaniwa
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Mee Kum Kim
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
| | - Kyoung Yul Seo
- Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University College of Medicine, Seoul, Korea
| | - Kyung-Chul Yoon
- Department of Ophthalmology, Chonnam National University, Gwangju, Korea
| | - Choun-Ki Joo
- Department of Ophthalmology & Visual Science, Seoul St Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea
| | - Chitra Kannabiran
- Prof Brien Holden Eye Research Centre, L V Prasad Eye Institute, Hyderabad, India
| | | | - Virender Sangwan
- Cornea and Anterior Segment Services, L V Prasad Eye Institute, Hyderabad, India
| | - Varsha Rathi
- Cornea and Anterior Segment Services, L V Prasad Eye Institute, Hyderabad, India
| | - Sayan Basu
- Cornea and Anterior Segment Services, L V Prasad Eye Institute, Hyderabad, India
| | - Takeshi Ozeki
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Taisei Mushiroda
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Emiko Sugiyama
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Keiko Maekawa
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Ryosuke Nakamura
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Michiko Aihara
- Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kayoko Matsunaga
- Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan
| | - Akihiro Sekine
- EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Junji Hamuro
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
| | - Michiaki Kubo
- Research Group for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Shigeru Kinoshita
- Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Katsushi Tokunaga
- Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
| |
Collapse
|
27
|
Otsuka M, Maeno Y, Fukami T, Inoue M, Tagami T, Ozeki T. Developmental considerations for ethanolates with regard to stability and physicochemical characterization of efonidipine hydrochloride ethanolate. CrystEngComm 2015. [DOI: 10.1039/c5ce00751h] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Efonidipine hydrochloride ethanolate arranges the chloride ion within a basket-type conformation. This distinctive crystal structure would contribute to the improvement of the API's thermal stability.
Collapse
Affiliation(s)
- M. Otsuka
- Analysis Research Department
- Nissan Chemical Industries, Ltd
- Funabashi-shi, Japan
| | - Y. Maeno
- Analysis Research Department
- Nissan Chemical Industries, Ltd
- Funabashi-shi, Japan
| | - T. Fukami
- Department of Molecular Pharmaceutics
- Meiji Pharmaceutical University
- Kiyose, Japan
| | - M. Inoue
- Department of Molecular Pharmaceutics
- Meiji Pharmaceutical University
- Kiyose, Japan
| | - T. Tagami
- Drug Delivery and Nano Pharmaceutics
- Graduate School of Pharmaceutical Sciences
- Nagoya City University
- Mizuho-ku, Japan
| | - T. Ozeki
- Drug Delivery and Nano Pharmaceutics
- Graduate School of Pharmaceutical Sciences
- Nagoya City University
- Mizuho-ku, Japan
| |
Collapse
|
28
|
Watanabe H, Tonooka E, Uno H, Ozeki T, Mushiroda T, Sueki H. Association between HLA‐B*13:01 and DIHS/DRESS due to dapson in a Japanese patients of pityriasis lichenoides et varioliformis acuta (PLEVA). Clin Transl Allergy 2014. [PMCID: PMC4128447 DOI: 10.1186/2045-7022-4-s3-p13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- Hideaki Watanabe
- Department of DermatologyShowa University School of MedicineJapan
| | - Erika Tonooka
- Department of DermatologyShowa University School of MedicineJapan
| | - Hirokazu Uno
- Department of DermatologyShowa University School of MedicineJapan
| | - Takeshi Ozeki
- RIKEN Center for Integrative Medical SciencesResearch Group for PharmacogenomicsJapan
| | - Taisei Mushiroda
- RIKEN Center for Integrative Medical SciencesResearch Group for PharmacogenomicsJapan
| | - Hirohiko Sueki
- Department of DermatologyShowa University School of MedicineJapan
| |
Collapse
|
29
|
Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, Furuya H, Ikeda H, Takahashi Y, Muramatsu M, Tohkin M, Ozeki T, Mushiroda T, Kubo M, Kamatani N, Abe M, Yagami A, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z, Matsunaga K, Aihara M. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics 2014; 14:1821-31. [PMID: 24236482 DOI: 10.2217/pgs.13.180] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM This preliminary study investigated genomic biomarkers for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), related to three antiepileptic drugs, zonisamide, phenobarbital and phenytoin. PATIENTS & METHODS HLA class I and HLA-DRB1 loci were genotyped for Japanese patients with zonisamide-, phenobarbital- or phenytoin-induced SJS/TEN (n = 12, 8 and 9, respectively) and for healthy Japanese volunteers (n = 2878). RESULTS Carrier frequencies of HLA-A*02:07 in patients with zonisamide-induced SJS/TEN and in the general Japanese population were 41.7 and 6.81%, respectively. Carrier frequencies of HLA-B*51:01 in patients with phenobarbital- and phenytoin-induced SJS/TEN and in controls were 75.0, 55.6 and 15.2%, respectively. HLA-A*02:07 and HLA-B*51:01, in a dominant model, were significantly associated with zonisamide- and phenobarbital-induced SJS/TEN, respectively (Pc = 0.0176 and 0.0042, respectively). CONCLUSION Our data suggest that HLA-A*02:07 and HLA-B*51:01 are potential biomarkers for zonisamide- and phenobarbital-induced SJS/TEN, respectively, in Japanese individuals.
Collapse
Affiliation(s)
- Nahoko Kaniwa
- Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan and The Japan Severe Adverse Reactions (JSAR) Research Group, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Ota S, Ozeki T, Hoshino H, Terao K. AB0547 Rapid and novel immune assay platform of serum tocilizumab concentration applied by quartz-crystal microbalance (QCM) biosensor system. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Imai S, Fukui M, Ozasa N, Ozeki T, Kurokawa M, Komatsu T, Kajiyama S. Eating vegetables before carbohydrates improves postprandial glucose excursions. Diabet Med 2013; 30:370-2. [PMID: 23167256 PMCID: PMC3674531 DOI: 10.1111/dme.12073] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Revised: 10/15/2012] [Accepted: 11/16/2012] [Indexed: 01/06/2023]
|
33
|
Ozeki T. 1028 POSTER Gabexate Mesilate Induces the Apoptosis of HepG2cells. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70671-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Kojima T, Antonio MR, Ozeki T. The effect of solvents on the dissociation and association of decavanadates. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311079803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
35
|
Ito T, Mikurube K, Hasegawa K, Kurasawa M, Naruke H, Ozeki T. Hybrid inorganic–organic layered crystals constructed by oxide clusters and surfactant. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311083620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, Ikezawa Z, Iijima M, Shiohara T, Hashimoto K, Kamatani N, Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2010; 20:1034-41. [PMID: 21149285 DOI: 10.1093/hmg/ddq537] [Citation(s) in RCA: 398] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
An anticonvulsant, carbamazepine (CBZ), is known to show incidences of cutaneous adverse drug reactions (cADRs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS). To identify a gene(s) susceptible to CBZ-induced cADRs, we conducted a genome-wide association study (GWAS) in 53 subjects with the CBZ-induced cADRs, including SJS, TEN and DIHS, and 882 subjects of a general population in Japan. Among the single nucleotide polymorphisms (SNPs) analyzed in the GWAS, 12 SNPs showed significant association with CBZ-induced cADRs, and rs1633021 showed the smallest P-value for association with CBZ-induced cADRs (P = 1.18 × 10⁻¹³). These SNPs were located within a 430 kb linkage disequilibrium block on chromosome 6p21.33, including the HLA-A locus. Thus, we genotyped the individual HLA-A alleles in 61 cases and 376 patients who showed no cADRs by administration of CBZ (CBZ-tolerant controls) and found that HLA-A*3101 was present in 60.7% (37/61) of the patients with CBZ-induced cADRs, but in only 12.5% (47/376) of the CBZ-tolerant controls (odds ratio = 10.8, 95% confidence interval 5.9-19.6, P = 3.64 × 10⁻¹⁵), implying that this allele has the 60.7% sensitivity and 87.5% specificity when we apply HLA-A*3101 as a risk predictor for CBZ-induced cADRs. Although DIHS is clinically distinguished from SJS and TEN, our data presented here have indicated that they share a common genetic factor as well as a common pathophysiological mechanism. Our findings should provide useful information for making a decision of individualized medication of anticonvulsants.
Collapse
Affiliation(s)
- Takeshi Ozeki
- Research Group for Pharmacogenomics, RIKEN Center for Genomic Medicine, Yokohama 230-0045, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Sun QF, Iwasa J, Ogawa D, Ishido Y, Sato S, Ozeki T, Sei Y, Yamaguchi K, Fujita M. Self-Assembled M24L48 Polyhedra and Their Sharp Structural Switch upon Subtle Ligand Variation. Science 2010; 328:1144-7. [DOI: 10.1126/science.1188605] [Citation(s) in RCA: 674] [Impact Index Per Article: 48.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
38
|
Ayuhara H, Takayanagi R, Okuyama K, Yoshimoto K, Ozeki T, Yokoyama H, Yamada Y. Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists. Int J Clin Oncol 2009; 14:518-24. [PMID: 19967488 DOI: 10.1007/s10147-009-0912-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2009] [Accepted: 05/24/2009] [Indexed: 11/24/2022]
Abstract
BACKGROUND The aim of this study was to estimate interindividual differences in the antiemetic effects of 5-HT(3) receptor antagonists by evaluating the influence of pharmacokinetics on 5-HT(3) receptor occupancies, based on receptor occupancy theory. METHODS We analyzed interindividual differences of 5-HT(3) receptor occupancies and antiemetic effects after the oral and/or intravenous administration of standard doses of the following 5-HT(3) receptor antagonists: azasetron, granisetron, indisetron, ondansetron, ramosetron, and tropisetron. RESULTS The interindividual difference between maximum and minimum 5-HT(3) receptor occupancies after oral administration ranged from 0.6% to 64.0%, and that difference after intravenous administration ranged from 0.6% to 29.6%. Following oral administration, the interindividual difference between maximum and minimum complete vomiting inhibition rates ranged from 0.2% to 16.1%. After intravenous administration, that difference ranged from 0.8% to 52.5%. CONCLUSION Interindividual differences in the clinical effects of 5-HT(3) receptor antagonists could be evaluated based on receptor occupancy theory, and the differences varied among drugs. Drug selection considering these individual variations might be useful for the patients who experienced vomiting associated with chemotherapy.
Collapse
Affiliation(s)
- Hideaki Ayuhara
- Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
| | | | | | | | | | | | | |
Collapse
|
39
|
Ozeki T, Takeuchi M, Suzuki M, Kitamura T, Takayanagi R, Yokoyama H, Yamada Y. Single nucleotide polymorphisms of 17beta-hydroxysteroid dehydrogenase type 7 gene: mechanism of estramustine-related adverse reactions? Int J Urol 2009; 16:836-41. [PMID: 19735314 DOI: 10.1111/j.1442-2042.2009.02374.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To investigate the influence of single nucleotide polymorphisms (SNP) on transcription of the 17beta-hydroxysteroid dehydrogenase (HSD17B7) gene. METHODS Luciferase reporter genes containing a 5'-flanking of the HSD17B7 gene, as well as the sequence around the SNP, were transfected into LNCaP and DU145 cells. Then, luciferase assays were carried out. RESULTS The presence of the G allele resulted in an increase of transcriptional activity derived from the 5'-flanking region of the HSD17B7 gene by 270% and 370% in LNCaP and DU145 cells, respectively. Transcriptional activity of the HSD17B7 gene containing the G allele was higher than that of the C allele. CONCLUSIONS The transcriptional activity of the HSD17B7 gene containing the G allele is higher than that of the C allele. This difference in HSD17B7 expression may regulate the risk of peripheral edema as an adverse reaction induced by estramustine phosphate sodium.
Collapse
Affiliation(s)
- Takeshi Ozeki
- Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
40
|
Matsunaga G, Aiba N, Shinohara K, Sakamoto Y, Isayama A, Takechi M, Suzuki T, Oyama N, Asakura N, Kamada Y, Ozeki T. Observation of an energetic-particle-driven instability in the wall-stabilized high-beta plasmas in the JT-60U tokamak. Phys Rev Lett 2009; 103:045001. [PMID: 19659361 DOI: 10.1103/physrevlett.103.045001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2009] [Indexed: 05/28/2023]
Abstract
We have observed a bursting mode in the high-beta plasmas above the ideal beta limit without a conducting wall. The mode frequency is chirping down as the mode amplitude increases, and its initial value is close to the precession frequency of the trapped energetic particle from the perpendicular neutral beams. The mode structure is radially extended with a peak around the q = 2 surface. This mode can finally trigger the resistive wall mode (RWM) despite enough plasma rotation for RWM stabilization. It is concluded that the mode is driven by trapped energetic particles. The mode is attributed to the interaction between the trapped energetic particles and a marginally stable mode in the wall-stabilized high-beta_{N} region.
Collapse
Affiliation(s)
- G Matsunaga
- Japan Atomic Energy Agency, Naka 311-0193, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Nozawa M, Yoshida M, Saito Y, Nakagawa M, Ozeki T, Yoshikawa M, Aono Y, Uemura H. Serum selenium and risk of prostate cancer in Japanese men. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16166 Background: Epidemiologic studies suggest that low selenium levels are associated with an increased incidence of prostate cancer, although results are conflicting. We examined the association between serum selenium levels and risk of prostate cancer in men who received a prostate biopsy in our hospital. Methods: Our prospective study included 82 patients who received a prostate biopsy based on elevated PSA levels over 4.0ng/ml. Serum from each patient was sampled to determine the selenium level at the time of biopsy. Of these, 47 patients were diagnosed with prostate cancer (case group) and no malignant lesions in the biopsy specimen were detected in the remains, 35 patients (control group). Results: The mean serum selenium levels in the case and control group were 120.4 (SD, 14.4) ng/mL and 118.5 (SD, 16.1) ng/mL, respectively (p = 0.588). Serum selenium levels at biopsy were not associated with risk of prostate cancer diagnosis. In the case group, the mean serum selenium levels in patients diagnosed with 6 or less in Gleason score and 7 or more were 121.0 (SD, 9.9) ng/mL (n = 14) and 120.1 (SD, 16.1) ng/mL (n = 33), respectively (p = 0.851). Serum selenium levels at biopsy were not associated with Gleason score in the case group. An inverse association between serum selenium and PSA levels at biopsy was observed (p = 0.030). No correlation was observed between serum selenium level and age at biopsy. Conclusions: From this study, serum selenium level cannot predict the result of prostate biopsy. The inverse association between serum selenium and PSA levels may suggest that low selenium levels are associated with an increased incidence of prostate cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Nozawa
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - M. Yoshida
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - Y. Saito
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - M. Nakagawa
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - T. Ozeki
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - M. Yoshikawa
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - Y. Aono
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| | - H. Uemura
- Kinki University School of Medicine, Osaka-Sayama, Japan; Kansai University, Suita, Japan
| |
Collapse
|
42
|
Komaba S, Okushi K, Ozeki T, Yui H, Katayama Y, Miura T, Saito T, Groult H. Polyacrylate Modifier for Graphite Anode of Lithium-Ion Batteries. ACTA ACUST UNITED AC 2009. [DOI: 10.1149/1.3086262] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Kojima T, Antonio M, Ozeki T. Solvent-driven association and dissociation of the hydrogen-bonded protonated decavanadate dimer. Acta Crystallogr A 2008. [DOI: 10.1107/s010876730808700x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Tashiro K, Hanesaka M, Yoshizawa Y, Ohhara T, Kurihara K, Kuroki R, Tamada T, Fujiwara S, Ozeki T, Takata M, Sasaki S, Kohara S. First success in direct evaluation of electron density distribution of polymer by X–N method. Acta Crystallogr A 2008. [DOI: 10.1107/s010876730809315x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
45
|
Tanaka I, Kusaka K, Tomoyori K, Niimura N, Ohhara T, Kurihara K, Hosoya T, Ozeki T. A new biological neutron diffractometer (iBIX) in J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
46
|
Kusaka K, Ohhara T, Kurihara K, Tanaka I, Hosoya T, Tomoyori K, Ozeki T, Niimura N. Optimization of design parameters of IBARAKI Biological Crystal Diffractometer (iBIX) in J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
47
|
Hanesaka M, Tashiro K, Yoshizawa Y, Kitano T, Nishu T, Ohhara T, Tanaka I, Niimura N, Kurihara K, Kuroki R, Tamada T, Fujiwara S, Ozeki T. Application of neutron imaging-plate system to crystal structure analysis of deuterated polymers. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308081865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023] Open
|
48
|
Ozeki T, Nakamura S, Busbongthong S. Incompatible host–guest strategy to enclathrate water clusters into polyoxometalate crystals. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308099248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
49
|
|
50
|
Oshima T, Kiyono K, Sakata S, Sato M, Kominato T, Ozeki T. Development of new mass data acquisition system for diagnostics on JT-60U. Fusion Engineering and Design 2008. [DOI: 10.1016/j.fusengdes.2007.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|